INTERNATIONAL PATENT: SHANGHAI BOFAN BIOTHERAPEUTICS CO., LTD., 上海博钒生物科技有限公司 FILES APPLICATION FOR "MONOCLONAL ANTIBODY AGAINST CAPSULAR POLYSACCHARIDE OF KLEBSIELLA PNEUMONIAE SEROTYPE K64, HYBRIDOMA CELL LINE THEREOF AND USE THEREOF"

GENEVA, July 7 -- SHANGHAI BOFAN BIOTHERAPEUTICS CO., LTD. (Building 10, No.860 Xinyang HighwayPudong New Area, Shanghai 201315), 上海博钒生物科技有限公司 (中国上海市浦东新区新杨公路860号10幢) filed a patent application (PCT/CN2024/138668) for "MONOCLONAL ANTIBODY AGAINST CAPSULAR POLYSACCHARIDE OF KLEBSIELLA PNEUMONIAE SEROTYPE K64, HYBRIDOMA CELL LINE THEREOF AND USE THEREOF" on Dec 12, 2024. With publication no. WO/2025/139807, the details related to the patent application was published on Jul 03, 2025.

Notably, the patent application was submitted under the International Paten...